1 Rare Disease Drug Market Overview 1.1 Product Overview and Scope of Rare Disease Drug 1.2 Rare Disease Drug Segment by Type 1.2.1 Global Rare Disease Drug Sales Growth Rate Comparison by Type (2022-2028) 1.2.2 Above 1‰ 1.2.3 0.65‰～1‰ 1.2.4 Below 0.1‰ 1.3 Rare Disease Drug Segment by Application 1.3.1 Global Rare Disease Drug Sales Comparison by Application: (2022-2028) 1.3.2 Hospital Pharmacies 1.3.3 Speciality Pharmacies 1.3.4 Retail pharmacies 1.3.5 Others 1.4 Global Rare Disease Drug Market Size Estimates and Forecasts 1.4.1 Global Rare Disease Drug Revenue 2017-2028 1.4.2 Global Rare Disease Drug Sales 2017-2028 1.4.3 Rare Disease Drug Market Size by Region: 2017 Versus 2021 Versus 2028 2 Rare Disease Drug Market Competition by Manufacturers 2.1 Global Rare Disease Drug Sales Market Share by Manufacturers (2017-2022) 2.2 Global Rare Disease Drug Revenue Market Share by Manufacturers (2017-2022) 2.3 Global Rare Disease Drug Average Price by Manufacturers (2017-2022) 2.4 Manufacturers Rare Disease Drug Manufacturing Sites, Area Served, Product Type 2.5 Rare Disease Drug Market Competitive Situation and Trends 2.5.1 Rare Disease Drug Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Rare Disease Drug Players Market Share by Revenue 2.5.3 Global Rare Disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Rare Disease Drug Retrospective Market Scenario by Region 3.1 Global Rare Disease Drug Retrospective Market Scenario in Sales by Region: 2017-2022 3.2 Global Rare Disease Drug Retrospective Market Scenario in Revenue by Region: 2017-2022 3.3 North America Rare Disease Drug Market Facts & Figures by Country 3.3.1 North America Rare Disease Drug Sales by Country 3.3.2 North America Rare Disease Drug Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Rare Disease Drug Market Facts & Figures by Country 3.4.1 Europe Rare Disease Drug Sales by Country 3.4.2 Europe Rare Disease Drug Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Rare Disease Drug Market Facts & Figures by Region 3.5.1 Asia Pacific Rare Disease Drug Sales by Region 3.5.2 Asia Pacific Rare Disease Drug Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Rare Disease Drug Market Facts & Figures by Country 3.6.1 Latin America Rare Disease Drug Sales by Country 3.6.2 Latin America Rare Disease Drug Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Rare Disease Drug Market Facts & Figures by Country 3.7.1 Middle East and Africa Rare Disease Drug Sales by Country 3.7.2 Middle East and Africa Rare Disease Drug Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Rare Disease Drug Historic Market Analysis by Type 4.1 Global Rare Disease Drug Sales Market Share by Type (2017-2022) 4.2 Global Rare Disease Drug Revenue Market Share by Type (2017-2022) 4.3 Global Rare Disease Drug Price by Type (2017-2022) 5 Global Rare Disease Drug Historic Market Analysis by Application 5.1 Global Rare Disease Drug Sales Market Share by Application (2017-2022) 5.2 Global Rare Disease Drug Revenue Market Share by Application (2017-2022) 5.3 Global Rare Disease Drug Price by Application (2017-2022) 6 Key Companies Profiled 6.1 Novartis AG 6.1.1 Novartis AG Corporation Information 6.1.2 Novartis AG Description and Business Overview 6.1.3 Novartis AG Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.1.4 Novartis AG Rare Disease Drug Product Portfolio 6.1.5 Novartis AG Recent Developments/Updates 6.2 Bristol-Myers Squibb Company 6.2.1 Bristol-Myers Squibb Company Corporation Information 6.2.2 Bristol-Myers Squibb Company Description and Business Overview 6.2.3 Bristol-Myers Squibb Company Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.2.4 Bristol-Myers Squibb Company Rare Disease Drug Product Portfolio 6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates 6.3 Celgene Corporation 6.3.1 Celgene Corporation Corporation Information 6.3.2 Celgene Corporation Description and Business Overview 6.3.3 Celgene Corporation Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.3.4 Celgene Corporation Rare Disease Drug Product Portfolio 6.3.5 Celgene Corporation Recent Developments/Updates 6.4 F. Hoffmann-La Roche Ltd. 6.4.1 F. Hoffmann-La Roche Ltd. Corporation Information 6.4.2 F. Hoffmann-La Roche Ltd. Description and Business Overview 6.4.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.4.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Portfolio 6.4.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates 6.5 Pfizer, Inc. 6.5.1 Pfizer, Inc. Corporation Information 6.5.2 Pfizer, Inc. Description and Business Overview 6.5.3 Pfizer, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.5.4 Pfizer, Inc. Rare Disease Drug Product Portfolio 6.5.5 Pfizer, Inc. Recent Developments/Updates 6.6 Sanofi S.A. 6.6.1 Sanofi S.A. Corporation Information 6.6.2 Sanofi S.A. Description and Business Overview 6.6.3 Sanofi S.A. Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.6.4 Sanofi S.A. Rare Disease Drug Product Portfolio 6.6.5 Sanofi S.A. Recent Developments/Updates 6.7 Alexion Pharmaceuticals, Inc. 6.6.1 Alexion Pharmaceuticals, Inc. Corporation Information 6.6.2 Alexion Pharmaceuticals, Inc. Description and Business Overview 6.6.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.4.4 Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Portfolio 6.7.5 Alexion Pharmaceuticals, Inc. Recent Developments/Updates 6.8 Eli Lilly and Company 6.8.1 Eli Lilly and Company Corporation Information 6.8.2 Eli Lilly and Company Description and Business Overview 6.8.3 Eli Lilly and Company Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.8.4 Eli Lilly and Company Rare Disease Drug Product Portfolio 6.8.5 Eli Lilly and Company Recent Developments/Updates 6.9 Novo Nordisk A/S 6.9.1 Novo Nordisk A/S Corporation Information 6.9.2 Novo Nordisk A/S Description and Business Overview 6.9.3 Novo Nordisk A/S Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.9.4 Novo Nordisk A/S Rare Disease Drug Product Portfolio 6.9.5 Novo Nordisk A/S Recent Developments/Updates 6.10 AstraZeneca 6.10.1 AstraZeneca Corporation Information 6.10.2 AstraZeneca Description and Business Overview 6.10.3 AstraZeneca Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.10.4 AstraZeneca Rare Disease Drug Product Portfolio 6.10.5 AstraZeneca Recent Developments/Updates 6.11 Eisai Co., Ltd. 6.11.1 Eisai Co., Ltd. Corporation Information 6.11.2 Eisai Co., Ltd. Rare Disease Drug Description and Business Overview 6.11.3 Eisai Co., Ltd. Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.11.4 Eisai Co., Ltd. Rare Disease Drug Product Portfolio 6.11.5 Eisai Co., Ltd. Recent Developments/Updates 6.12 Daiichi Sankyo Company Limited 6.12.1 Daiichi Sankyo Company Limited Corporation Information 6.12.2 Daiichi Sankyo Company Limited Rare Disease Drug Description and Business Overview 6.12.3 Daiichi Sankyo Company Limited Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.12.4 Daiichi Sankyo Company Limited Rare Disease Drug Product Portfolio 6.12.5 Daiichi Sankyo Company Limited Recent Developments/Updates 6.13 Bayer AG 6.13.1 Bayer AG Corporation Information 6.13.2 Bayer AG Rare Disease Drug Description and Business Overview 6.13.3 Bayer AG Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.13.4 Bayer AG Rare Disease Drug Product Portfolio 6.13.5 Bayer AG Recent Developments/Updates 6.14 GlaxoSmithKline 6.14.1 GlaxoSmithKline Corporation Information 6.14.2 GlaxoSmithKline Rare Disease Drug Description and Business Overview 6.14.3 GlaxoSmithKline Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.14.4 GlaxoSmithKline Rare Disease Drug Product Portfolio 6.14.5 GlaxoSmithKline Recent Developments/Updates 6.15 Merck & Co., Inc. 6.15.1 Merck & Co., Inc. Corporation Information 6.15.2 Merck & Co., Inc. Rare Disease Drug Description and Business Overview 6.15.3 Merck & Co., Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.15.4 Merck & Co., Inc. Rare Disease Drug Product Portfolio 6.15.5 Merck & Co., Inc. Recent Developments/Updates 6.16 Johnson & Johnson 6.16.1 Johnson & Johnson Corporation Information 6.16.2 Johnson & Johnson Rare Disease Drug Description and Business Overview 6.16.3 Johnson & Johnson Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.16.4 Johnson & Johnson Rare Disease Drug Product Portfolio 6.16.5 Johnson & Johnson Recent Developments/Updates 6.17 Biogen, Inc. 6.17.1 Biogen, Inc. Corporation Information 6.17.2 Biogen, Inc. Rare Disease Drug Description and Business Overview 6.17.3 Biogen, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.17.4 Biogen, Inc. Rare Disease Drug Product Portfolio 6.17.5 Biogen, Inc. Recent Developments/Updates 6.18 Takeda 6.18.1 Takeda Corporation Information 6.18.2 Takeda Rare Disease Drug Description and Business Overview 6.18.3 Takeda Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.18.4 Takeda Rare Disease Drug Product Portfolio 6.18.5 Takeda Recent Developments/Updates 6.19 Amgen, Inc. 6.19.1 Amgen, Inc. Corporation Information 6.19.2 Amgen, Inc. Rare Disease Drug Description and Business Overview 6.19.3 Amgen, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.19.4 Amgen, Inc. Rare Disease Drug Product Portfolio 6.19.5 Amgen, Inc. Recent Developments/Updates 6.20 Deciphera 6.20.1 Deciphera Corporation Information 6.20.2 Deciphera Rare Disease Drug Description and Business Overview 6.20.3 Deciphera Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.20.4 Deciphera Rare Disease Drug Product Portfolio 6.20.5 Deciphera Recent Developments/Updates 6.21 Atara Biotherapeutics 6.21.1 Atara Biotherapeutics Corporation Information 6.21.2 Atara Biotherapeutics Rare Disease Drug Description and Business Overview 6.21.3 Atara Biotherapeutics Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.21.4 Atara Biotherapeutics Rare Disease Drug Product Portfolio 6.21.5 Atara Biotherapeutics Recent Developments/Updates 6.22 ProQR 6.22.1 ProQR Corporation Information 6.22.2 ProQR Rare Disease Drug Description and Business Overview 6.22.3 ProQR Rare Disease Drug Sales, Revenue and Gross Margin (2017-2022) 6.22.4 ProQR Rare Disease Drug Product Portfolio 6.22.5 ProQR Recent Developments/Updates 7 Rare Disease Drug Manufacturing Cost Analysis 7.1 Rare Disease Drug Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Rare Disease Drug 7.4 Rare Disease Drug Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Rare Disease Drug Distributors List 8.3 Rare Disease Drug Customers 9 Rare Disease Drug Market Dynamics 9.1 Rare Disease Drug Industry Trends 9.2 Rare Disease Drug Market Drivers 9.3 Rare Disease Drug Market Challenges 9.4 Rare Disease Drug Market Restraints 10 Global Market Forecast 10.1 Rare Disease Drug Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Rare Disease Drug by Type (2023-2028) 10.1.2 Global Forecasted Revenue of Rare Disease Drug by Type (2023-2028) 10.2 Rare Disease Drug Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Rare Disease Drug by Application (2023-2028) 10.2.2 Global Forecasted Revenue of Rare Disease Drug by Application (2023-2028) 10.3 Rare Disease Drug Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Rare Disease Drug by Region (2023-2028) 10.3.2 Global Forecasted Revenue of Rare Disease Drug by Region (2023-2028) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Rare Disease Drug Sales Growth Rate Comparison by Type (2022-2028) & (K Doses) & (US$ Million) Table 2. Global Rare Disease Drug Sales Growth Rate Comparison by Application (2022-2028) & (K Doses) & (US$ Million) Table 3. Global Rare Disease Drug Market Size by Region (US$ Million) (2017 VS 2021 VS 2028) Table 4. Global Rare Disease Drug Market Competitive Situation by Manufacturers in 2021 Table 5. Global Rare Disease Drug Sales (K Doses) of Key Manufacturers (2017-2022) Table 6. Global Rare Disease Drug Sales Market Share by Manufacturers (2017-2022) Table 7. Global Rare Disease Drug Revenue (US$ Million) by Manufacturers (2017-2022) Table 8. Global Rare Disease Drug Revenue Share by Manufacturers (2017-2022) Table 9. Global Market Rare Disease Drug Average Price (USD/Dose) of Key Manufacturers (2017-2022) Table 10. Manufacturers Rare Disease Drug Manufacturing Sites and Area Served Table 11. Manufacturers Rare Disease Drug Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Rare Disease Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Rare Disease Drug as of 2021) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Rare Disease Drug Sales by Region (2017-2022) & (K Doses) Table 16. Global Rare Disease Drug Sales Market Share by Region (2017-2022) Table 17. Global Rare Disease Drug Revenue by Region (2017-2022) & (US$ Million) Table 18. Global Rare Disease Drug Revenue Market Share by Region (2017-2022) Table 19. North America Rare Disease Drug Sales by Country (2017-2022) & (K Doses) Table 20. North America Rare Disease Drug Sales Market Share by Country (2017-2022) Table 21. North America Rare Disease Drug Revenue by Country (2017-2022) & (US$ Million) Table 22. North America Rare Disease Drug Revenue Market Share by Country (2017-2022) Table 23. Europe Rare Disease Drug Sales by Country (2017-2022) & (K Doses) Table 24. Europe Rare Disease Drug Sales Market Share by Country (2017-2022) Table 25. Europe Rare Disease Drug Revenue by Country (2017-2022) & (US$ Million) Table 26. Europe Rare Disease Drug Revenue Market Share by Country (2017-2022) Table 27. Asia Pacific Rare Disease Drug Sales by Region (2017-2022) & (K Doses) Table 28. Asia Pacific Rare Disease Drug Sales Market Share by Region (2017-2022) Table 29. Asia Pacific Rare Disease Drug Revenue by Region (2017-2022) & (US$ Million) Table 30. Asia Pacific Rare Disease Drug Revenue Market Share by Region (2017-2022) Table 31. Latin America Rare Disease Drug Sales by Country (2017-2022) & (K Doses) Table 32. Latin America Rare Disease Drug Sales Market Share by Country (2017-2022) Table 33. Latin America Rare Disease Drug Revenue by Country (2017-2022) & (US$ Million) Table 34. Latin America Rare Disease Drug Revenue Market Share by Country (2017-2022) Table 35. Middle East and Africa Rare Disease Drug Sales by Country (2017-2022) & (K Doses) Table 36. Middle East and Africa Rare Disease Drug Sales Market Share by Country (2017-2022) Table 37. Middle East and Africa Rare Disease Drug Revenue by Country (2017-2022) & (US$ Million) Table 38. Middle East and Africa Rare Disease Drug Revenue Market Share by Country (2017-2022) Table 39. Global Rare Disease Drug Sales by Type (2017-2022) & (K Doses) Table 40. Global Rare Disease Drug Sales Market Share by Type (2017-2022) Table 41. Global Rare Disease Drug Revenue by Type (2017-2022) & (US$ Million) Table 42. Global Rare Disease Drug Revenue Share by Type (2017-2022) Table 43. Global Rare Disease Drug Price by Type (2017-2022) & (USD/Dose) Table 44. Global Rare Disease Drug Sales (K Doses) by Application (2017-2022) Table 45. Global Rare Disease Drug Sales Market Share by Application (2017-2022) Table 46. Global Rare Disease Drug Revenue by Application (2017-2022) & (US$ Million) Table 47. Global Rare Disease Drug Revenue Share by Application (2017-2022) Table 48. Global Rare Disease Drug Price by Application (2017-2022) & (USD/Dose) Table 49. Novartis AG Corporation Information Table 50. Novartis AG Description and Business Overview Table 51. Novartis AG Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 52. Novartis AG Rare Disease Drug Product Table 53. Novartis AG Recent Developments/Updates Table 54. Bristol-Myers Squibb Company Corporation Information Table 55. Bristol-Myers Squibb Company Description and Business Overview Table 56. Bristol-Myers Squibb Company Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 57. Bristol-Myers Squibb Company Rare Disease Drug Product Table 58. Bristol-Myers Squibb Company Recent Developments/Updates Table 59. Celgene Corporation Corporation Information Table 60. Celgene Corporation Description and Business Overview Table 61. Celgene Corporation Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 62. Celgene Corporation Rare Disease Drug Product Table 63. Celgene Corporation Recent Developments/Updates Table 64. F. Hoffmann-La Roche Ltd. Corporation Information Table 65. F. Hoffmann-La Roche Ltd. Description and Business Overview Table 66. F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 67. F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Table 68. F. Hoffmann-La Roche Ltd. Recent Developments/Updates Table 69. Pfizer, Inc. Corporation Information Table 70. Pfizer, Inc. Description and Business Overview Table 71. Pfizer, Inc. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 72. Pfizer, Inc. Rare Disease Drug Product Table 73. Pfizer, Inc. Recent Developments/Updates Table 74. Sanofi S.A. Corporation Information Table 75. Sanofi S.A. Description and Business Overview Table 76. Sanofi S.A. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 77. Sanofi S.A. Rare Disease Drug Product Table 78. Sanofi S.A. Recent Developments/Updates Table 79. Alexion Pharmaceuticals, Inc. Corporation Information Table 80. Alexion Pharmaceuticals, Inc. Description and Business Overview Table 81. Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 82. Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Table 83. Alexion Pharmaceuticals, Inc. Recent Developments/Updates Table 84. Eli Lilly and Company Corporation Information Table 85. Eli Lilly and Company Description and Business Overview Table 86. Eli Lilly and Company Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 87. Eli Lilly and Company Rare Disease Drug Product Table 88. Eli Lilly and Company Recent Developments/Updates Table 89. Novo Nordisk A/S Corporation Information Table 90. Novo Nordisk A/S Description and Business Overview Table 91. Novo Nordisk A/S Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 92. Novo Nordisk A/S Rare Disease Drug Product Table 93. Novo Nordisk A/S Recent Developments/Updates Table 94. AstraZeneca Corporation Information Table 95. AstraZeneca Description and Business Overview Table 96. AstraZeneca Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 97. AstraZeneca Rare Disease Drug Product Table 98. AstraZeneca Recent Developments/Updates Table 99. Eisai Co., Ltd. Corporation Information Table 100. Eisai Co., Ltd. Description and Business Overview Table 101. Eisai Co., Ltd. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 102. Eisai Co., Ltd. Rare Disease Drug Product Table 103. Eisai Co., Ltd. Recent Developments/Updates Table 104. Daiichi Sankyo Company Limited Corporation Information Table 105. Daiichi Sankyo Company Limited Description and Business Overview Table 106. Daiichi Sankyo Company Limited Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 107. Daiichi Sankyo Company Limited Rare Disease Drug Product Table 108. Daiichi Sankyo Company Limited Recent Developments/Updates Table 109. Bayer AG Corporation Information Table 110. Bayer AG Description and Business Overview Table 111. Bayer AG Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 112. Bayer AG Rare Disease Drug Product Table 113. Bayer AG Recent Developments/Updates Table 114. GlaxoSmithKline Corporation Information Table 115. GlaxoSmithKline Description and Business Overview Table 116. GlaxoSmithKline Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 117. GlaxoSmithKline Rare Disease Drug Product Table 118. GlaxoSmithKline Recent Developments/Updates Table 119. Merck & Co., Inc. Corporation Information Table 120. Merck & Co., Inc. Description and Business Overview Table 121. Merck & Co., Inc. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 122. Merck & Co., Inc. Rare Disease Drug Product Table 123. Merck & Co., Inc. Recent Developments/Updates Table 124. Johnson & Johnson Corporation Information Table 125. Johnson & Johnson Description and Business Overview Table 126. Johnson & Johnson Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 127. Johnson & Johnson Rare Disease Drug Product Table 128. Johnson & Johnson Recent Developments/Updates Table 129. Biogen, Inc. Corporation Information Table 130. Biogen, Inc. Description and Business Overview Table 131. Biogen, Inc. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 132. Biogen, Inc. Rare Disease Drug Product Table 133. Biogen, Inc. Recent Developments/Updates Table 134. Takeda Corporation Information Table 135. Takeda Description and Business Overview Table 136. Takeda Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 137. Takeda Rare Disease Drug Product Table 138. Takeda Recent Developments/Updates Table 139. Amgen, Inc. Corporation Information Table 140. Amgen, Inc. Description and Business Overview Table 141. Amgen, Inc. Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 142. Amgen, Inc. Rare Disease Drug Product Table 143. Amgen, Inc. Recent Developments/Updates Table 144. Deciphera Corporation Information Table 145. Deciphera Description and Business Overview Table 146. Deciphera Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 147. Deciphera Rare Disease Drug Product Table 148. Deciphera Recent Developments/Updates Table 149. Atara Biotherapeutics Corporation Information Table 150. Atara Biotherapeutics Description and Business Overview Table 151. Atara Biotherapeutics Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 152. Atara Biotherapeutics Rare Disease Drug Product Table 153. Atara Biotherapeutics Recent Developments/Updates Table 154. ProQR Corporation Information Table 155. ProQR Description and Business Overview Table 156. ProQR Rare Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 157. ProQR Rare Disease Drug Product Table 158. ProQR Recent Developments/Updates Table 159. Production Base and Market Concentration Rate of Raw Material Table 160. Key Suppliers of Raw Materials Table 161. Rare Disease Drug Distributors List Table 162. Rare Disease Drug Customers List Table 163. Rare Disease Drug Market Trends Table 164. Rare Disease Drug Market Drivers Table 165. Rare Disease Drug Market Challenges Table 166. Rare Disease Drug Market Restraints Table 167. Global Rare Disease Drug Sales Forecast by Type (2023-2028) & (K Doses) Table 168. Global Rare Disease Drug Sales Market Share Forecast by Type (2023-2028) Table 169. Global Rare Disease Drug Revenue Forecast by Type (2023-2028) & (US$ Million) Table 170. Global Rare Disease Drug Revenue Market Share Forecast by Type (2023-2028) Table 171. Global Rare Disease Drug Sales Forecast by Application (2023-2028) & (K Doses) Table 172. Global Rare Disease Drug Sales Market Share Forecast by Application (2023-2028) Table 173. Global Rare Disease Drug Revenue Forecast by Application (2023-2028) & (US$ Million) Table 174. Global Rare Disease Drug Revenue Market Share Forecast by Application (2023-2028) Table 175. Global Rare Disease Drug Sales Forecast by Region (2023-2028) & (K Doses) Table 176. Global Rare Disease Drug Sales Market Share Forecast by Region (2023-2028) Table 177. Global Rare Disease Drug Revenue Forecast by Region (2023-2028) & (US$ Million) Table 178. Global Rare Disease Drug Revenue Market Share Forecast by Region (2023-2028) Table 179. Research Programs/Design for This Report Table 180. Key Data Information from Secondary Sources Table 181. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Rare Disease Drug Figure 2. Global Rare Disease Drug Market Share by Type in 2021 & 2028 Figure 3. Above 1‰ Product Picture Figure 4. 0.65‰～1‰ Product Picture Figure 5. Below 0.1‰ Product Picture Figure 6. Global Rare Disease Drug Market Share by Application in 2021 & 2028 Figure 7. Hospital Pharmacies Figure 8. Speciality Pharmacies Figure 9. Retail pharmacies Figure 10. Others Figure 11. Global Rare Disease Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 12. Global Rare Disease Drug Market Size (2017-2028) & (US$ Million) Figure 13. Global Rare Disease Drug Sales (2017-2028) & (K Doses) Figure 14. Rare Disease Drug Sales Share by Manufacturers in 2021 Figure 15. Global Rare Disease Drug Revenue Share by Manufacturers in 2021 Figure 16. The Global 5 and 10 Largest Rare Disease Drug Players: Market Share by Revenue in 2021 Figure 17. Rare Disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 18. Global Rare Disease Drug Sales Market Share by Region (2017-2022) Figure 19. Global Rare Disease Drug Sales Market Share by Region in 2021 Figure 20. Global Rare Disease Drug Revenue Market Share by Region (2017-2022) Figure 21. Global Rare Disease Drug Revenue Market Share by Region in 2021 Figure 22. U.S. Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 23. Canada Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 24. Germany Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 25. France Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 26. U.K. Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 27. Italy Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 28. Russia Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 29. China Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 30. Japan Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 31. South Korea Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 32. India Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 33. Australia Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 34. Taiwan Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 35. Indonesia Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 36. Thailand Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 37. Malaysia Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 38. Philippines Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 39. Vietnam Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 40. Mexico Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 41. Brazil Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 42. Argentina Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 43. Turkey Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 44. Saudi Arabia Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 45. U.A.E Rare Disease Drug Revenue Growth Rate (2017-2022) & (US$ Million) Figure 46. Sales Market Share of Rare Disease Drug by Type (2017-2022) Figure 47. Manufacturing Cost Structure of Rare Disease Drug Figure 48. Manufacturing Process Analysis of Rare Disease Drug Figure 49. Rare Disease Drug Industrial Chain Analysis Figure 50. Channels of Distribution Figure 51. Distributors Profiles Figure 52. Bottom-up and Top-down Approaches for This Report Figure 53. Data Triangulation Figure 54. Key Executives Interviewed

Novartis AG Bristol-Myers Squibb Company Celgene Corporation F. Hoffmann-La Roche Ltd. Pfizer, Inc. Sanofi S.A. Alexion Pharmaceuticals, Inc. Eli Lilly and Company Novo Nordisk A/S AstraZeneca Eisai Co., Ltd. Daiichi Sankyo Company Limited Bayer AG GlaxoSmithKline Merck & Co., Inc. Johnson & Johnson Biogen, Inc. Takeda Amgen, Inc. Deciphera Atara Biotherapeutics ProQR